# Rituximab Plus Chemotherapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

> **NCT04361409** · PHASE1 · COMPLETED · sponsor: **China Medical University Hospital** · enrollment: 10 (actual)

## Conditions studied

- Head and Neck Squamous Carcinoma

## Interventions

- **DRUG:** Rituximab
- **DRUG:** Cisplatin
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT04361409
- **Lead sponsor:** China Medical University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05
- **Primary completion:** 2016-11
- **Final completion:** 2017-01
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2020-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04361409

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04361409, "Rituximab Plus Chemotherapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04361409. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*